Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 13/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586937 | 1.00 | PTGER4 (0.41) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18133252 | 0.77 | PTGER4 (0.35) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16841379 | 0.76 | PTGER4 (0.50) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16841384 | 0.76 | PTGER4 (0.50) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18943758 | 0.75 | PTGER4 (0.32) | PTGER4PTGER2PTGER3 | |
| SCHEMBL21119072 | 0.73 | PTGER4 (0.34) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15587106 | 0.73 | PTGER4 (0.34) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16088563 | 0.70 | PTGER4 (0.38) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16092649 | 0.70 | PTGER4 (0.38) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16088695 | 0.70 | PTGER4 (0.38) | PTGER4PTGER2PTGER3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3175852-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2874620-B1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2875022-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |